Xi-Putin Talks Show Deepening Bond Between Russia and China

Key Takeaways

• Power of Siberia 2 stalled over price dispute, not technical issues
• China's gas imports could equal pre‑war Europe shipments
• China cut US Treasury holdings to lowest since 2008
• China approved first commercial brain‑computer implant, $1.7 bn funded
• Russia‑China trade doubled 2020‑2024, oil up 35%

Pulse Analysis

The Xi‑Putin summit in Beijing highlighted an accelerating convergence between two of the world’s biggest authoritarian powers. Both leaders framed their relationship as "the highest level in history," a rhetoric that masks a pragmatic bargain over the Power of Siberia 2 pipeline. The 2,600‑kilometre conduit would enable China to purchase up to half of Russia’s gas output—roughly the volume Moscow once shipped to Europe—yet negotiations have stalled as Beijing pushes for prices near half of Moscow’s expectations. This impasse reflects a broader shift: Russia’s reliance on Chinese demand has grown as Western markets close, while China leverages its buying power to secure cheaper energy amid a volatile global market.

Beyond energy, the meeting coincided with China’s decisive financial repositioning. In March, Beijing trimmed its U.S. Treasury holdings to the lowest level since 2008, a move amplified by the Iran‑triggered sell‑off that pushed the 30‑year yield to 5.2%, its highest since 2007. The reduction signals waning confidence in the dollar‑denominated safe‑haven and hints at a gradual diversification of China’s foreign‑exchange reserves, especially as its trade surplus nears $1.2 trillion. For investors, the shift underscores rising bond‑market volatility and potential re‑pricing of risk assets worldwide.

Meanwhile, China leapt ahead in the race for brain‑computer interfaces, granting commercial approval to Neuracle’s implant and earmarking $1.7 billion to dominate a market projected at $320 billion by 2030. The technology, already showing promise in restoring motor function for spinal‑injury patients, is being treated as a strategic national priority, contrasting sharply with the cautious U.S. FDA approach to Neuralink. This aggressive push not only accelerates China’s biotech sector but also raises geopolitical stakes, as control over neuro‑technology could translate into new forms of military and intelligence advantage. Together, the energy, financial, and tech dimensions of the Xi‑Putin dialogue illustrate a coordinated effort to reshape global power structures away from Western hegemony.